Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposures to their allergens. We are currently conducting a Phase 3 study of our lead product, AR101 for the treatment of peanut allergy.
Type
Public
HQ
Brisbane, US
Founded
2011
Employees
54 (est)

Aimmune Therapeutics Locations

Brisbane, US

Aimmune Therapeutics Metrics

Aimmune Therapeutics Summary

Founding Date

2011

Market capitalization

$943 M

Closing share price

$22

Aimmune Therapeutics Market Value History

Aimmune Therapeutics News

Aimmune Therapeutics Company Life

You may also be interested in